Vaxcyte, Inc.

PCVX Healthcare Biotechnology

EPS
−61.5%
Free cash flow
−92.6%

Quarter to June 2026, against a year earlier

63.82 1.90 +3.07%
Market cap
$9.8B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

Vaxcyte, Inc. (PCVX) Book value per share

Alert me on Book value per share

Vaxcyte, Inc.'s book value per share at the end of fiscal 2025 was 19.7×, down 27.2% from 27.1× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 19.1×. Over the past ten years it has ranged from 5.5× (fiscal 2021) to 27.1× (fiscal 2024); the current reading is higher than 88% of that period. Vaxcyte, Inc. ranks 37th of 611 Biotechnology companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 19.7× (27.18%)
FY2024 27.1× 112.24%
FY2023 12.8× (13.14%)
FY2022 14.7× 168.71%
FY2021 5.5× (53.27%)
FY2020 11.7× (17.64%)
FY2019 14.2× (14.13%)
FY2018 16.6× —

Quarterly newest first

Period Book value per share Change
Jun 2026 19.1× (11.12%)
Mar 2026 21.5× 8.83%
Dec 2025 19.7× (7.10%)
Sep 2025 21.2× (5.92%)
26 more quarters

Against its own ten years

Low 5.5× High 27.1×
Ten-year median 14.5×
Current reading's percentile 88

Book value per share against peers

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on PCVX